Crossmark

Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort

Crossref DOI link: https://doi.org/10.1038/s41408-024-01150-3

Published Online: 2024-09-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Enemark, Marie Hairing https://orcid.org/0000-0003-4086-5183
Hemmingsen, Jonas Klejs

Andersen, Maja Dam

Hybel, Trine Engelbrecht

Bjørn, Mads Emil

Josefsson, Pär Lars

Pedersen, Lars Møller

Juul, Maja Bech

Pedersen, Robert Schou

Thorsgaard, Michael

Sillesen, Ida Blok

Plesner, Trine Lindhardt

Hamilton-Dutoit, Stephen Jacques https://orcid.org/0000-0003-2158-3885
Jensen, Paw https://orcid.org/0000-0002-5248-0523
Madsen, Charlotte

Ludvigsen, Maja https://orcid.org/0000-0001-5089-3271
License Information

Text and Data Mining valid from 2024-09-30

Version of Record valid from 2024-09-30
More Information

Article History

Received: 14 May 2024

Revised: 18 September 2024

Accepted: 19 September 2024

First Online: 30 September 2024

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below